Cargando…

Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin

Triheptanoin is an odd‐carbon, medium‐chain triglyceride consisting of three fatty acids with seven carbons each on a glycerol backbone, indicated for the treatment of adult and pediatric patients with long‐chain fatty acid oxidation disorders (LC‐FAOD). A total of 562 plasma concentrations of hepta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sun Ku, Gosselin, Nathalie H., Jomphe, Claudia, McKeever, Kathleen, Putnam, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795984/ https://www.ncbi.nlm.nih.gov/pubmed/35908210 http://dx.doi.org/10.1002/cpdd.1145

Ejemplares similares

The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders
por: Lee, Sun Ku, et al.
Publicado: (2021)

Benzylammonium heptanoate–heptanoic acid (1/1)
por: Wood, Mary H., et al.
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Benzylammonium heptanoate
por: Wood, Mary H., et al.
Publicado: (2013)

Heptanoate Improves Compensatory Mechanism of Glucose Homeostasis in Mitochondrial Long-Chain Fatty Acid Oxidation Defect
por: Nurjanah, Siti, et al.
Publicado: (2023)

Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders
por: Sklirou, Evgenia, et al.
Publicado: (2021)

Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020)

Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders
por: Zöggeler, Thomas, et al.
Publicado: (2021)

Correction to: Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020)

Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency
por: Engelstad, Kristin, et al.
Publicado: (2021)

Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
por: Borges, Karin, et al.
Publicado: (2019)

No effect of triheptanoin on exercise performance in McArdle disease
por: Madsen, Karen L., et al.
Publicado: (2019)

Combination of triheptanoin with the ketogenic diet in Glucose transporter type 1 deficiency (G1D)
por: Avila, Adrian, et al.
Publicado: (2023)

Effects of triheptanoin (UX007) in patients with long‐chain fatty acid oxidation disorders: Results from an open‐label, long‐term extension study
por: Vockley, Jerry, et al.
Publicado: (2020)

Metabolism and pharmacokinetics of medium chain fatty acids after oral administration of royal jelly to healthy subjects
por: Yamaga, Masayuki, et al.
Publicado: (2019)

Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D)
por: Málaga, Ignacio, et al.
Publicado: (2023)

Triheptanoin – Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency
por: Laemmle, Alexander, et al.
Publicado: (2021)

Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency
por: Mochel, Fanny, et al.
Publicado: (2016)

Crystal structure, Hirshfeld surface analysis, interaction energy, and DFT studies of cholesteryl heptanoate
por: Akduran, Nurcan, et al.
Publicado: (2021)

Seven new metabolites of drostanolone heptanoate by using Beauveria bassiana, and Macrophomina phaseolina cell suspension cultures
por: Hussain, Zahid, et al.
Publicado: (2020)

Dietary management and major clinical events in patients with longchain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study
por: Vockley, Jerry, et al.
Publicado: (2020)

A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood
por: Hainque, Elodie, et al.
Publicado: (2017)

Open‐label long‐term treatment of add‐on triheptanoin in adults with drug‐resistant epilepsy
por: Borges, Karin, et al.
Publicado: (2020)

Demulsification of Emulsion Using Heptanoic Acid during Aqueous Enzymatic Extraction and the Characterization of Peanut Oil and Proteins Extracted
por: Li, Tianci, et al.
Publicado: (2023)

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
por: Luedtke, Doreen, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
por: Qi, Yulan, et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
por: Marier, Jean‐Francois, et al.
Publicado: (2021)

Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis
por: Tefera, Tesfaye W., et al.
Publicado: (2016)

A randomized, double‐blind trial of triheptanoin for drug‐resistant epilepsy in glucose transporter 1 deficiency syndrome
por: Striano, Pasquale, et al.
Publicado: (2022)

Achieving a healthy home food environment: perspectives on parents’ nutrition education needs when living with food insecurity
por: Oliver, Tracy, et al.
Publicado: (2023)

Propofol pharmacokinetics in young healthy Indian subjects
por: Puri, Avinash, et al.
Publicado: (2012)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
por: Bratsos, Sosipatros
Publicado: (2019)

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2019)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ucvhulqarasl9o85aeorbc7hvg